StemCellFactory III Consortium

Within the multidisciplinary StemCellFactory III consortium leading partners in stem cell science, production technology, compound development, medicinal product compliance and project management have joint forces to develop novel automated cell manufacturing technologies and predictive iPSC-based cellular resources for diseases modeling and therapy advancement in the field of neuropsychatric diseases. The three-year project is based on a Europe-wide unique platform technology for automated reprogramming and expansion of iPSCs. The project started in July 2017 and is funded with € 2.4 million from the Leitmarktwettbewerb LifeSience.NRW and the European Regional Development Fund (EFRE).